Evidence map›Paper›PMID 38376808›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Effectiveness of [

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Stephen Ahenkorah, Anjong Florence Tikum, Emmanuel Nwangele, Nikita Henning, Frederik Cleeren, Humphrey Fonge

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Preclinical characterization of 3p-C-DEPAEJNMMI radiopharmacy and chemistry · 2025
    Article
  6. New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.Anti-cancer agents in medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica Pougoue KetchemenDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Fabrice Ngoh NjotuDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Hanan BabekerDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Stephen AhenkorahNURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium.
Anjong Florence TikumDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Emmanuel NwangeleDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Nikita HenningDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada.
Frederik CleerenRadiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium.
Humphrey FongeDepartment of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, SK, S7N 0W8, Canada. humphrey.fonge@usask.ca.ORCID 0000-0001-9388-6872

Funding

Institute of Cancer Research 408132Institute of Cancer Research 437660
6 · The paper itself

Abstract

purposeTo evaluate the imaging and therapeutic properties (theranostic) of

methodsWe conjugated trastuzumab with p-SCN-Bn-NOTA, 3p-C-NETA-NCS, or p-SCN-Bn-DOTA, and radiolabeled with [

resultsPure immunoconjugates and radioimmunoconjugates (> 95%) were obtained. Internalization was HER2 density-dependent with highest internalization observed with NOTA-trastuzumab. After 5 days, in vitro stabilities were 97 ± 1.7%, 31 ± 6.2%, and 28 ± 4% in HS, and 79 ± 3.5%, 94 ± 1.2%, and 86 ± 2.3% in PBS for [

conclusion[

Indexed as

Breast NeoplasmsCopper RadioisotopesErb-b2 Receptor Tyrosine KinasesTrastuzumabAnimalsCell Line, TumorFemaleHumansImmunoconjugatesMiceRadiopharmaceuticalsTheranostic NanomedicineTissue DistributionCopper-67Copper RadioisotopesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesRadiopharmaceuticalsTrastuzumab67CuDosimetryHER2-positive breast cancerp-SCN-Bn-NOTATheranostics

Identifiers

PMID38376808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.